Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2202083A
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK2202083A is an investigational **heptavalent pediatric combination vaccine** developed by GSK. It combines diphtheria and tetanus toxoids, acellular pertussis antigens, recombinant hepatitis B surface antigen, inactivated poliovirus types 1, 2, and 3, *Haemophilus influenzae* type b capsular polysaccharide conjugated to tetanus toxoid, and meningococcal serogroup C capsular polysaccharide conjugated to tetanus toxoid. The vaccine was evaluated in Phase 2 infant primary-vaccination and booster studies for prevention of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, invasive Hib disease, and meningococcal serogroup C disease. No marketed brand name or regulatory approval for this exact investigational combination has been identified.
- Other names
- DTPa-HBV-IPV/Hib-MenC-TTGSK 2202083AGSK2202083AGSK-2202083Aheptavalent combination vaccineheptavalent conjugated vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideFIM2/FIM3 (Fimbriae types 2 and 3)HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)Hib conjugate (Haemophilus influenzae type b capsular polysaccharide-protein conjugate)
Beyond the preview
Go deeper on GSK2202083A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2202083A.